Literature DB >> 19064950

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Emilio Bajetta, Valentina Guadalupi, Giuseppe Procopio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19064950     DOI： 10.1200/JCO.2008.20.3034

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

Authors:  Yanji Luo; Jie Chen; Kun Huang; Yuan Lin; Minhu Chen; Ling Xu; Zi-Ping Li; Shi-Ting Feng
Journal:  BMC Cancer       Date:  2017-02-23       Impact factor: 4.430

2.  A side-by-side evaluation of [18F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography.

Authors:  Athira Narayan; Yu Yan; Ala Lisok; Mary Brummet; Martin G Pomper; Wojciech G Lesniak; Robert F Dannals; Vanessa F Merino; Babak Behnam Azad
Journal:  Oncotarget       Date:  2019-10-08

3.  KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.

Authors:  Fei Yuan; Min Shi; Jun Ji; Hailong Shi; Chenfei Zhou; Yingyan Yu; Bingya Liu; Zhenggang Zhu; Jun Zhang
Journal:  Int J Biol Sci       Date:  2014-08-30       Impact factor: 6.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.